CAMBRIDGE, Mass., Dec. 19,
2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for
clinically proven kinase targets in cancer, today announced that
James Porter, Ph.D., Chief Executive
Officer, will present at the 43rd Annual J.P. Morgan
Healthcare Conference on Tuesday, January
14, 2025, at 9:00 a.m. PT in
San Francisco.
A live webcast will be available in the Investors section of the
company's website at www.nuvalent.com, and archived for 30 days
following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for patients
with cancer, designed to overcome the limitations of existing
therapies for clinically proven kinase targets. Leveraging deep
expertise in chemistry and structure-based drug design, we develop
innovative small molecules that have the potential to overcome
resistance, minimize adverse events, address brain metastases, and
drive more durable responses. Nuvalent is advancing a robust
pipeline with investigational candidates for ROS1-positive,
ALK-positive, and HER2-altered non-small cell lung cancer, and
multiple discovery-stage research programs.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302335786.html
SOURCE Nuvalent, Inc.